Baricitinib
- TRADE NAME: Olumiant (Eli Lilly and Co)
- INDICATIONS: Treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. Treatment of atopic dermatitis.
- CLASS: Covid-19 putative drug, Janus kinase (JAK) inhibitor
- HALF-LIFE: ~12 hours
FDA APPROVAL DATE: 05/31/2018
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: N/A
Insufficient data to inform a drug-associated risk for major birth defects or miscarriage
Investigated for treating COVID-19.
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), AND THROMBOSIS (amended December 2021)
• INCREASED RISK OF SERIOUS BACTERIAL, FUNGAL, VIRAL AND OPPORTUNISTIC INFECTIONS LEADING TO HOSPITALIZATION OR DEATH, INCLUDING TUBERCULOSIS (TB). INTERRUPT TREATMENT WITH BARICITINIB IF SERIOUS INFECTION OCCURS UNTIL THE INFECTION IS CONTROLLED. TEST FOR LATENT TB BEFORE AND DURING THERAPY; TREAT LATENT TB PRIOR TO USE. MONITOR ALL PATIENTS FOR ACTIVE TB DURING TREATMENT, EVEN PATIENTS WITH INITIAL NEGATIVE, LATENT TB TEST.
• HIGHER RATE OF ALL-CAUSE MORTALITY, INCLUDING SUDDEN CARDIOVASCULAR DEATH WITH ANOTHER JANUS KINASE INHIBITOR (JAK) VS. TNF BLOCKERS IN RHEUMATOID ARTHRITIS (RA) PATIENTS.
• MALIGNANCIES HAVE OCCURRED IN PATIENTS TREATED WITH BARICITINIB. HIGHER RATE OF LYMPHOMAS AND LUNG CANCERS WITH ANOTHER JAK INHIBITOR VS. TNF BLOCKERS IN RA PATIENTS.
• HIGHER RATE OF MACE (DEFINED AS CARDIOVASCULAR DEATH, MYOCARDIAL INFARCTION, AND STROKE) WITH ANOTHER JAK INHIBITOR VS. TNF BLOCKERS IN RA PATIENTS.
• THROMBOSIS HAS OCCURRED IN PATIENTS TREATED WITH BARICITINIB. INCREASED INCIDENCE OF PULMONARY EMBOLISM, VENOUS AND ARTERIAL THROMBOSIS WITH ANOTHER JAK INHIBITOR VS. TNF
See full prescribing information for complete boxed warning
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of baricitinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 02/16/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric